In a report issued on July 9, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Natera (NASDAQ: NTRA), with a price target of $25. The company’s shares closed yesterday at $20.58, close to its 52-week high of $22.54.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.4% and a 63.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Idexx Laboratories, and Exact Sciences.
Currently, the analyst consensus on Natera is a Strong Buy with an average price target of $22.25, an 8.1% upside from current levels. In a report issued on June 28, Robert W. Baird also maintained a Buy rating on the stock with a $20 price target.
Based on Natera’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $32.87 million. In comparison, last year the company had a GAAP net loss of $27.73 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.